- Home
- KOS vs PHAT Comparison
KOS vs PHAT Comparison
Compare KOS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOS
- PHAT
- Stock Information
- Founded
- KOS 2003
- PHAT 2018
- Country
- KOS United States
- PHAT United States
- Employees
- KOS N/A
- PHAT N/A
- Industry
- KOS Oil & Gas Production
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- KOS Energy
- PHAT Health Care
- Exchange
- KOS Nasdaq
- PHAT Nasdaq
- Market Cap
- KOS 798.7M
- PHAT 942.6M
- IPO Year
- KOS 2011
- PHAT 2019
- Fundamental
- Price
- KOS $1.45
- PHAT $14.66
- Analyst Decision
- KOS Hold
- PHAT Strong Buy
- Analyst Count
- KOS 5
- PHAT 5
- Target Price
- KOS $3.40
- PHAT $17.60
- AVG Volume (30 Days)
- KOS 9.4M
- PHAT 968.0K
- Earning Date
- KOS 11-03-2025
- PHAT 10-30-2025
- Dividend Yield
- KOS N/A
- PHAT N/A
- EPS Growth
- KOS N/A
- PHAT N/A
- EPS
- KOS N/A
- PHAT N/A
- Revenue
- KOS $1,392,234,000.00
- PHAT $147,190,000.00
- Revenue This Year
- KOS N/A
- PHAT $218.38
- Revenue Next Year
- KOS $16.52
- PHAT $87.14
- P/E Ratio
- KOS N/A
- PHAT N/A
- Revenue Growth
- KOS N/A
- PHAT 460.30
- 52 Week Low
- KOS $1.34
- PHAT $2.21
- 52 Week High
- KOS $4.22
- PHAT $16.08
- Technical
- Relative Strength Index (RSI)
- KOS 42.98
- PHAT 67.17
- Support Level
- KOS $1.37
- PHAT $13.79
- Resistance Level
- KOS $1.59
- PHAT $14.22
- Average True Range (ATR)
- KOS 0.10
- PHAT 0.99
- MACD
- KOS 0.00
- PHAT 0.06
- Stochastic Oscillator
- KOS 28.38
- PHAT 63.13
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.